Spectral Diagnostics (DIAGF) 0.2750 $DIAGF
Spectral Announces Effective Date of Name Change
Marketwired - Tue Dec 16, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that its previously announced name change to "Spectral Medical Inc." will be effective December 31, 2014. This new name will reflect the Company's continuing transition into a therapeutic development company, with a strategic focus on the development and commercialization of a treatment for severe sepsis and septic shock using our Endotoxin Activity Assay and the Toraymyxin(TM) ("PMX" therapeutic.
SDI.TO: 0.34 (-0.01)
Spectral Announces Normal Course Issuer Bid
Marketwired - Mon Dec 15, 7:02AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI)(OTCQX: DIAGF) a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the Toronto Stock Exchange ("TSX" has accepted Spectral's notice of intention to proceed with a normal course issuer bid through the facilities of the TSX.
SDI.TO: 0.34 (-0.01)
Largest Japanese Registry Data Analysis Demonstrates Significant Reduction in Mortality Rate of Septic Patients Treated With Toraymyxin(TM)
Marketwired - Tue Nov 25, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the presentation of the largest ever analysis of Japanese registry data on the significant mortality rate reduction in patients with septic shock treated with Toraymyxin(TM) ("PMX" .The results of the study and analysis were presented at the American Society of Nephrology and support Spectral's EUPHRATES trial design.
SDI.TO: 0.34 (-0.01)
Spectral Diagnostics reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:15AM CST
Spectral Announces Third Quarter 2014 Results
Marketwired - Thu Nov 13, 7:07AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced its unaudited financial results for the three and nine month periods ended September 30, 2014.
SDI.TO: 0.34 (-0.01)
Spectral Provides Update on Its Path to Commercialization
Marketwired - Wed Nov 05, 7:05AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today provided an update on the Company's recent and upcoming activities, demonstrating a clear commercialization path to address the critical care needs of patients in a $3 billion market.
SDI.TO: 0.34 (-0.01)
Spectral to Exhibit at the Critical Care Canada Forum
CNW Group - Wed Oct 29, 7:00AM CDT
Dr. Claudio Ronco to discuss his analysis on the importance of endotoxin removal
SDI.TO: 0.34 (-0.01)
Spectral announces board changes
CNW Group - Wed Sep 24, 4:24PM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that Mr. William Stevens has been appointed to its Board of Directors.
SDI.TO: 0.34 (-0.01)
Spectral Announces Second Quarter, 2014 Results
CNW Group - Wed Aug 13, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2014.
SDI.TO: 0.34 (-0.01)
Spectral Diagnostics and Toray Industries announce closing of Tranche "A" component of its up to $18.2 million Offering
CNW Group - Fri Jul 25, 8:26AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or"Spectral" and Toray Industries, Inc. ("Toray" today announced the closing of Tranche "A" of the previously announced non-brokered private placement of the Corporation (the "Offering" . The Tranche "A" component of the Offering was comprised of 45,051,186 common shares of the Corporation ("Shares" ,at a subscription price of $0.293 per Share for aggregate proceeds of $13.2 million. The Offering was approved by shareholders of the Corporation at a special meeting of shareholders held on July 22, 2014.
SDI.TO: 0.34 (-0.01)
Spectral Diagnostics announces shareholder approval of its up to $18.2 million offering
CNW Group - Tue Jul 22, 1:26PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral" today announced that at the special meeting (the "Special Meeting" of shareholders ("Shareholders" of the Corporation held earlier today, Shareholders overwhelmingly approved the terms of the previously announced proposed non-brokered private placement of the Corporation of up to $18.2 million (the "Offering" .
SDI.TO: 0.34 (-0.01)
Spectral Announces ISS and Glass Lewis Recommendations to Vote in Favour of its up to $18.2 Million Offering
CNW Group - Tue Jul 08, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral" today announced that both ISS Proxy Advisory Services and Glass Lewis & Co. have endorsed the previously announced non-brokered private placement of the Corporation of up to $18.2 million (the "Proposed Offering" and recommend that shareholders of Spectral ("Shareholders" vote "FOR" the Proposed Offering at the upcoming special meeting of Shareholders to be held on July 22, 2014.
SDI.TO: 0.34 (-0.01)
Spectral Announces Effective Date of Name Change
Marketwired - Tue Dec 16, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that its previously announced name change to "Spectral Medical Inc." will be effective December 31, 2014. This new name will reflect the Company's continuing transition into a therapeutic development company, with a strategic focus on the development and commercialization of a treatment for severe sepsis and septic shock using our Endotoxin Activity Assay and the Toraymyxin(TM) ("PMX" therapeutic. SDI.TO: 0.34 (-0.01)
Spectral Announces Normal Course Issuer Bid
Marketwired - Mon Dec 15, 7:02AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF) a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the Toronto Stock Exchange ("TSX" has accepted Spectral's notice of intention to proceed with a normal course issuer bid through the facilities of the TSX. SDI.TO: 0.34 (-0.01)
Largest Japanese Registry Data Analysis Demonstrates Significant Reduction in Mortality Rate of Septic Patients Treated With Toraymyxin(TM)
Marketwired - Tue Nov 25, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the presentation of the largest ever analysis of Japanese registry data on the significant mortality rate reduction in patients with septic shock treated with Toraymyxin(TM) ("PMX" .The results of the study and analysis were presented at the American Society of Nephrology and support Spectral's EUPHRATES trial design. SDI.TO: 0.34 (-0.01)
Spectral Diagnostics reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:15AM CST
Spectral Announces Third Quarter 2014 Results
Marketwired - Thu Nov 13, 7:07AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced its unaudited financial results for the three and nine month periods ended September 30, 2014. SDI.TO: 0.34 (-0.01)
Spectral Provides Update on Its Path to Commercialization
Marketwired - Wed Nov 05, 7:05AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today provided an update on the Company's recent and upcoming activities, demonstrating a clear commercialization path to address the critical care needs of patients in a $3 billion market. SDI.TO: 0.34 (-0.01)
Spectral to Exhibit at the Critical Care Canada Forum
CNW Group - Wed Oct 29, 7:00AM CDT
Dr. Claudio Ronco to discuss his analysis on the importance of endotoxin removal
SDI.TO: 0.34 (-0.01)
Spectral announces board changes
CNW Group - Wed Sep 24, 4:24PM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that Mr. William Stevens has been appointed to its Board of Directors.
SDI.TO: 0.34 (-0.01)
Spectral Announces Second Quarter, 2014 Results
CNW Group - Wed Aug 13, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2014.
SDI.TO: 0.34 (-0.01)
Spectral Diagnostics and Toray Industries announce closing of Tranche "A" component of its up to $18.2 million Offering
CNW Group - Fri Jul 25, 8:26AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or"Spectral"
and Toray Industries, Inc. ("Toray" today announced the closing of Tranche "A" of the previously announced non-brokered private placement of the Corporation (the "Offering" . The Tranche "A" component of the Offering was comprised of 45,051,186 common shares of the Corporation ("Shares" ,at a subscription price of $0.293 per Share for aggregate proceeds of $13.2 million. The Offering was approved by shareholders of the Corporation at a special meeting of shareholders held on July 22, 2014. SDI.TO: 0.34 (-0.01)
Spectral Diagnostics announces shareholder approval of its up to $18.2 million offering
CNW Group - Tue Jul 22, 1:26PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral"
today announced that at the special meeting (the "Special Meeting" of shareholders ("Shareholders" of the Corporation held earlier today, Shareholders overwhelmingly approved the terms of the previously announced proposed non-brokered private placement of the Corporation of up to $18.2 million (the "Offering" . SDI.TO: 0.34 (-0.01)
Spectral Announces ISS and Glass Lewis Recommendations to Vote in Favour of its up to $18.2 Million Offering
CNW Group - Tue Jul 08, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral"
today announced that both ISS Proxy Advisory Services and Glass Lewis & Co. have endorsed the previously announced non-brokered private placement of the Corporation of up to $18.2 million (the "Proposed Offering" and recommend that shareholders of Spectral ("Shareholders" vote "FOR" the Proposed Offering at the upcoming special meeting of Shareholders to be held on July 22, 2014. SDI.TO: 0.34 (-0.01)
